ON DEMAND: ASH 2021 – Highlights through an Australian lens – non malignant haematology

Watch again as an expert panel present their highlights in non-malignant haematology from the 2021 American Society of Haematology Annual Meeting and discuss the impacts for practice. Hosted by...

Watch again as an expert panel present their highlights in non-malignant haematology from the 2021 American Society of...

ON DEMAND: ASH 2021 – Highlights through an Australian lens – malignant haematology

Watch again as an expert panel present their highlights in malignant haematology from the 2021 American Society of Haematology Annual Meeting and discuss the impacts for practice. Hosted by Associate Professor John...

Watch again as an expert panel present their highlights in malignant haematology from the 2021 American Society of...
Blood cancers

Study shows indicators of venetoclax response in therapy-related myeloid neoplasm

Venetoclax can induce deep remission in a subset of patients with aggressive therapy-related myeloid neoplasm (t-MN), according to research conducted at the Mayo Clinic and the Central Adelaide Health Network. A retrospective review of 367 WHO-defined cases of t-MN was presented...

Venetoclax can induce deep remission in a subset of patients with aggressive therapy-related myeloid neoplasm (t-MN), according to research conducted...